Perrigo Company plc Loss Contingency, Receivable, Current
Perrigo Company plc (PRGO) had Loss Contingency, Receivable, Current of $83.40 million as of 2021-10-02, per its 10-Q filed 2021-11-12.
Discontinued › Notes › Commitment and Contingencies › Loss Contingency › Loss Contingency, Related Receivable
us-gaap:LossContingencyReceivableCurrent · last filed 2021-11-12
- 2021-10-02: Loss Contingency, Receivable, Current $83.40M.
- 2021-07-03: Loss Contingency, Receivable, Current $56.20M.
- 2021-04-03: Loss Contingency, Receivable, Current $65.00M.
| Period end | Loss Contingency, Receivable, Current |
|---|---|
| 2021-10-02 | $83.40M 10-Q · filed 2021-11-12 |
| 2021-07-03 | $56.20M 10-Q · filed 2021-08-11 |
| 2021-04-03 | $65.00M 10-Q · filed 2021-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |